MedPage Today December 12, 2024
— Patent thickets another key target
Policy experts punched holes in drug companies’ claims that the Medicare Drug Price Negotiation Program will stunt innovation and weighed in on other drug price-curbing strategies during a webinar hosted by the National Institute for Health Care Management (NIHCM) Foundation on Wednesday.
The Backlash to Medicare Drug Price Negotiation
A number of pharmaceutical companies and other stakeholders have fought the drug price negotiation program in courts, with some arguing that the program will stifle innovation and reduce access to drugs for vulnerable patients.
However, Gregg Girvan, MPP, a fellow for the Foundation for Research on Equal Opportunity (FREOPP), said the policy won’t be nearly as damaging to innovation as pharmaceutical companies have warned.
Girvan...
Today's Sponsors
Today's Sponsor